Cascadian Investor Says $614M Deal Statement Omitted Info
A shareholder of biopharmaceutical company Cascadian Therapeutics Inc. launched a class action on Tuesday in Delaware federal court alleging the company's directors omitted material information from documents detailing a proposed $614...To view the full article, register now.
Already a subscriber? Click here to view full article